Abstract
The number of antiarrhythmic drugs available in the United States is increasing, with the discovery of antiarrhythmic properties of drugs previously marketed for other indications (phenytoin, imipramine) and the development of several new drugs, many of which are likely to become commercially available in the next 5 years. The currently available drugs and several promising investigational drugs are reviewed in this report. Their optimal use is dependent on an understanding of their electropharmacologic effects, pharmacokinetics, drug interactions, and clinical pharmacology. Such use may allow better attempts to reduce arrhythmia-related death and morbidity.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
-
Review
MeSH terms
-
Adrenergic beta-Antagonists / therapeutic use
-
Amiodarone / therapeutic use
-
Anilides / therapeutic use
-
Anti-Arrhythmia Agents / metabolism
-
Anti-Arrhythmia Agents / therapeutic use*
-
Benzeneacetamides*
-
Biological Availability
-
Bretylium Compounds / therapeutic use
-
Disopyramide / therapeutic use
-
Encainide
-
Flecainide
-
Humans
-
Imipramine / therapeutic use
-
Lidocaine / analogs & derivatives
-
Lidocaine / therapeutic use
-
Mexiletine / therapeutic use
-
Moricizine
-
Phenothiazines / therapeutic use
-
Phenytoin / therapeutic use
-
Piperidines / therapeutic use
-
Procainamide / therapeutic use
-
Propafenone
-
Propiophenones / therapeutic use
-
Quinidine / therapeutic use
-
Tocainide
Substances
-
Adrenergic beta-Antagonists
-
Anilides
-
Anti-Arrhythmia Agents
-
Benzeneacetamides
-
Bretylium Compounds
-
Phenothiazines
-
Piperidines
-
Propiophenones
-
Mexiletine
-
Tocainide
-
Moricizine
-
Phenytoin
-
Propafenone
-
Lidocaine
-
Disopyramide
-
Quinidine
-
Flecainide
-
lorcainide
-
Procainamide
-
Amiodarone
-
Imipramine
-
bretylium
-
Encainide